Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.

Resumen detallado
Moderna's melanoma vaccine plus Keytruda cut the risk of recurrence or death by 42% in Phase 3, yet the stock sank. Here's why.
Moderna (MRNA -4.84%) delivered promising results for its experimental cancer vaccine on Oct. 22, yet its stock plunged anyway. But looking past the headlines, there's more to the story than the trial results suggest, and investors may be overlooking the real opportunity.
At first glance, Moderna delivered the kind of clinical milestone that investors had been waiting for: positive Phase 3 results for its personalized melanoma vaccine, intismeran autogene, developed in partnership with Merck. But despite the solid results, Moderna shares fell more than 25% during the Oct. 22 session.
The sell-off followed an unexpected leak of the trial results ahead of their scheduled presentation at the European Society for Medical Oncology (ESMO) Congress. In the trial, the vaccine, when administered alongside Merck's Keytruda, reduced the risk of cancer recurrence or death by 42% compared with Keytruda alone.
On paper, these were encouraging results, but Moderna stock had already rallied following an earlier Phase 2 study. Indeed, this appears to be the case of the market wanting something even better.
For example, some analysts expected the Phase 3 hazard ratio to come in below 0.60, which would mean the vaccine reduces the risk of recurrence or death by more than 40%. Yet the actual result came in at 0.58, which technically cleared that threshold, but only narrowly.
In the end, given the high expectations, investors viewed the results as a disappointment. But there's more here than the headline numbers suggest.
Several analysts softened their initial views after the full presentation, recognizing that the vaccine delivered a meaningful improvement over Keytruda alone. The vaccine requires a series of personalized immunizations, which reduced the risk of recurrence or death by 58% based on outcomes six months or more after the initial treatment.
On top of that, the safety profile was notable. In fact, serious treatment-related adverse events occurred in around 10% of patients…
That…
Inicio del artículo, extracto de The Motley Fool. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)




